ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development

  ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma
  Compound into Preclinical Development

Business Wire

SAN DIEGO -- June 3, 2013

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today announced
that Allergan, Inc. (NYSE: AGN) has advanced an additional product candidate
as a potential new treatment for glaucoma. The novel small molecule resulted
from joint research conducted by the companies under their recently concluded
research collaboration focused on new therapies for glaucoma and related
ophthalmic conditions.

“We are delighted that Allergan has advanced another new chemical entity
emerging from our collaborative research into preclinical development,” said
Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. “This molecule has
demonstrated an attractive profile and has distinctly different properties
from other glaucoma compounds advanced under the collaboration. This program
benefits greatly from Allergan’s expertise and leadership in the eye care
field and further illustrates the combined strength of our joint discovery
capabilities.”

Allergan is responsible for development and has worldwide rights to
commercialize products advanced under the companies’ glaucoma collaboration.
ACADIA is eligible to receive payments upon the successful achievement of
clinical and regulatory milestones as well as royalties on future worldwide
product sales, if any.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two
advanced preclinical programs directed at Parkinson’s disease and other
neurological disorders. All product candidates are small molecules that
emanate from discoveries made at ACADIA. ACADIA maintains a website at
www.acadia-pharm.com to which ACADIA regularly posts copies of its press
releases as well as additional information and through which interested
parties can subscribe to receive email alerts.

Forward-Looking Statements

This press release contains statements that are forward-looking, including
statements regarding the timing and results from our research and development
programs, the benefits to be derived from such programs, including those in
collaboration with Allergan, the potential for new therapies for glaucoma or
other ophthalmic conditions, potential development or commercialization of the
product candidate, and potential future milestone payments or royalties from
Allergan. These statements are only predictions based on current information
and expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of such
statements due to various factors, including the risks and uncertainties
associated with drug discovery and development, including the fact that past
results may not be indicative of future results. For a discussion of these and
other factors, please refer to ACADIA’s annual report on Form 10-K for the
year ended December31, 2012 as well as other subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. This caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and ACADIA undertakes
no obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.

Contact:

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
(858) 558-2871